Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6(7):1961-1968.

The model that the authors used to calculate fludarabine pharmacokinetics was based on a different article than what was cited as reference 19 on page 1962 under “Outcomes of interest.” Therefore, reference 19 on page 1968 should read as follows:

19. Ivaturi V, Dvorak CC, Chan D, et al. Pharmacokinetics and model-based dosing to optimize fludarabine therapy in pediatric hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2017;23(10):1701-1713.